Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Viral Meningitis

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...

Bacterial Meningitis I: Introduction

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Bacterial Meningitis II: Pathophysiology

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...

Antiepileptic Drugs: Glutamate Antagonists

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment, and Management of Suspected Acute Drug-Induced Liver Injury Occurring during Clinical Trials: Consensus Recommendations from the IQ DILI Initiative.

Drug safety·2025

Same author

Amiodarone and Dronedarone Causes Liver Injury with Distinctly Different Clinical Presentations.

Digestive diseases and sciences·2024

Same author

Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.

Journal of hepatology·2023

Same author

Assessment of the Impact of Mandated Postmarketing Pediatric-Focused Safety Reviews on Safety-Related Regulatory Actions 2013-2019.

Clinical pharmacology and therapeutics·2023

Same author

Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration.

JAMA internal medicine·2022

Same author

Co-Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver-Chip for the Study of Drug-Induced Liver Injury.

Current protocols·2022

Search research articles

Related Experiment Video

Updated: May 24, 2026

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection

Published on: May 7, 2020

Lamotrigine and aseptic meningitis.

Kelley M Simms¹, Cindy Kortepeter, Mark Avigan

¹Food and Drug Administration, Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology, Silver Spring, MD, USA. Kelley.Simms@fda.hhs.gov

|February 24, 2012

Summary

This study suggests a link between lamotrigine, an antiepileptic drug, and aseptic meningitis. Nearly 40% of cases showed a positive rechallenge, indicating a potential drug-associated adverse event.

More Related Videos

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Related Experiment Videos

Last Updated: May 24, 2026

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection

Published on: May 7, 2020

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

Area of Science:

Neurology
Pharmacovigilance
Clinical Pharmacology

Background:

Antiepileptic drugs (AEDs) are crucial for managing epilepsy.
Aseptic meningitis is a rare but serious neurological condition.
Identifying drug-specific associations is vital for patient safety.

Observation:

Analysis of the FDA Adverse Event Reporting System (AERS) database identified cases of aseptic meningitis.
A data mining approach using the MGPS algorithm was applied to 9 AEDs.
Lamotrigine was disproportionately reported in association with aseptic meningitis.

Findings:

Forty cases of aseptic meningitis linked to lamotrigine were identified.
Cerebrospinal fluid profiles showed characteristics of both bacterial and viral meningitis.
Fifteen cases had a positive rechallenge, with a median symptom onset of 60 minutes.

Implications:

A potential association between lamotrigine and aseptic meningitis is suggested.
Lamotrigine-associated aseptic meningitis should be considered in diagnosing culture-negative meningitis.
This highlights the need for ongoing pharmacovigilance and patient monitoring for AEDs.